Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002317.SZ

Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2023: USD 63.63 M

Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA is USD 63.63 M for the year ending December 31, 2023, a -19.11% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2022 was USD 78.66 M, a 4.27% change year over year.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2021 was USD 75.43 M, a 337.85% change year over year.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2020 was USD -31.72 M, a -142.04% change year over year.
Guangdong Zhongsheng Pharmaceutical Co., Ltd. EBITDA for the year ending December 31, 2019 was USD 75.45 M, a -15.14% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Shenzhen Stock Exchange: 002317.SZ

Guangdong Zhongsheng Pharmaceutical Co., Ltd.

CEO	Mr. Yong Hong Chen
IPO Date	Dec. 11, 2009
Location	China
Headquarters	Information Industry Park
Employees	1,732
Sector	Health Care
Industries Pharmaceuticals

Description

Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. The company offers Chinese and chemical medicines. It is also involved in the research and development of products in the fields of ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor, and senile degenerative diseases. The company was founded in 1979 and is based in Dongguan, China.

Key trends

Past 5 years